Pharming Launches Joenja in Japan for APDS Patients
LEIDEN, Netherlands, August 13, 2026 Pharming Group N.V. announced the commercial launch of Joenja® (leniolisib) in Japan for adults...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
LEIDEN, Netherlands, August 13, 2026 Pharming Group N.V. announced the commercial launch of Joenja® (leniolisib) in Japan for adults...
TOKYO, August 7, 2026 Astellas Pharma announced the submission of a New Drug Application (NDA) to Japan’s Ministry of...
WILMINGTON, Del., June 20, 2026 Incyte Biosciences Japan G.K. has announced that Japan’s Ministry of Health, Labour and Welfare...
LONDON, United Kingdom, May 20, 2026 GSK has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved...
